Western Europe Cancer Chemotherapy Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Western Europe Cancer Chemotherapy Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Western Europe Cancer Chemotherapy Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Western Europe Cancer Chemotherapy Market Regional Analysis

6.2 Western Europe Cancer Chemotherapy Market Revenue 2021-2031 (US$ Million)

6.3 Western Europe Cancer Chemotherapy Market Forecast Analysis

7. Western Europe Cancer Chemotherapy Market Analysis – by Therapy Type

7.1 Alkylating Agents

7.1.1 Overview
7.1.2 Alkylating Agents: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

7.2 Antimetabolites

7.2.1 Overview
7.2.2 Antimetabolites: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

7.3 Anti-Tumor Antibiotics

7.3.1 Overview
7.3.2 Anti-Tumor Antibiotics: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

7.4 Topoisomerase Inhibitors

7.4.1 Overview
7.4.2 Topoisomerase Inhibitors: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

7.5 Mitotic Inhibitors

7.5.1 Overview
7.5.2 Mitotic Inhibitors: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

7.6 Other Therapy Type

7.6.1 Overview
7.6.2 Other Therapy Type: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

8. Western Europe Cancer Chemotherapy Market Analysis – by Indication

8.1 Blood Cancer

8.1.1 Overview
8.1.2 Blood Cancer: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

8.2 Lung Cancer

8.2.1 Overview
8.2.2 Lung Cancer: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

8.3 Breast Cancer

8.3.1 Overview
8.3.2 Breast Cancer: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

8.4 Colorectum Cancer

8.4.1 Overview
8.4.2 Colorectum Cancer: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

8.5 Prostate Cancer

8.5.1 Overview
8.5.2 Prostate Cancer: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

8.6 Stomach Cancer

8.6.1 Overview
8.6.2 Stomach Cancer: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

8.7 Cervical Cancer

8.7.1 Overview
8.7.2 Cervical Cancer: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

8.8 Liver and Intrahepatic Bile Duct Cancer

8.8.1 Overview
8.8.2 Liver and Intrahepatic Bile Duct Cancer: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

8.9 Thyroid Cancer

8.9.1 Overview
8.9.2 Thyroid Cancer: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

8.10 Other Indications

8.10.1 Overview
8.10.2 Other Indications: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

9. Western Europe Cancer Chemotherapy Market Analysis – by End User

9.1 Hospital Pharmacies

9.1.1 Overview
9.1.2 Hospital Pharmacies: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

9.2 Retail Pharmacies

9.2.1 Overview
9.2.2 Retail Pharmacies: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

9.3 Online Stores

9.3.1 Overview
9.3.2 Online Stores: Western Europe Cancer Chemotherapy Market – Revenue and Forecast, 2021-2031 (US$ Million)

10. Western Europe Cancer Chemotherapy Market – Western Europe Analysis

10.1 Overview

10.2 Western Europe

10.2.1 Western Europe Cancer Chemotherapy Market Breakdown, by Key Country, 2025 and 2031 (%)
10.2.1.1 Western Europe Cancer Chemotherapy Market – Revenue and Forecast Analysis – by Country
10.2.1.1 Belgium: Western Europe Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)

10.2.1.1.1 Belgium: Western Europe Cancer Chemotherapy Market Breakdown, by Therapy Type
10.2.1.1.2 Belgium: Western Europe Cancer Chemotherapy Market Breakdown, by Indication
10.2.1.1.3 Belgium: Western Europe Cancer Chemotherapy Market Breakdown, by End User

10.2.1.2 the Netherlands: Western Europe Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)

10.2.1.2.1 the Netherlands: Western Europe Cancer Chemotherapy Market Breakdown, by Therapy Type
10.2.1.2.2 the Netherlands: Western Europe Cancer Chemotherapy Market Breakdown, by Indication
10.2.1.2.3 the Netherlands: Western Europe Cancer Chemotherapy Market Breakdown, by End User

10.2.1.3 Luxembourg: Western Europe Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)

10.2.1.3.1 Luxembourg: Western Europe Cancer Chemotherapy Market Breakdown, by Therapy Type
10.2.1.3.2 Luxembourg: Western Europe Cancer Chemotherapy Market Breakdown, by Indication
10.2.1.3.3 Luxembourg: Western Europe Cancer Chemotherapy Market Breakdown, by End User

10.2.1.4 Germany: Western Europe Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)

10.2.1.4.1 Germany: Western Europe Cancer Chemotherapy Market Breakdown, by Therapy Type
10.2.1.4.2 Germany: Western Europe Cancer Chemotherapy Market Breakdown, by Indication
10.2.1.4.3 Germany: Western Europe Cancer Chemotherapy Market Breakdown, by End User

10.2.1.5 France: Western Europe Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)

10.2.1.5.1 France: Western Europe Cancer Chemotherapy Market Breakdown, by Therapy Type
10.2.1.5.2 France: Western Europe Cancer Chemotherapy Market Breakdown, by Indication
10.2.1.5.3 France: Western Europe Cancer Chemotherapy Market Breakdown, by End User

10.2.1.6 Italy: Western Europe Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)

10.2.1.6.1 Italy: Western Europe Cancer Chemotherapy Market Breakdown, by Therapy Type
10.2.1.6.2 Italy: Western Europe Cancer Chemotherapy Market Breakdown, by Indication
10.2.1.6.3 Italy: Western Europe Cancer Chemotherapy Market Breakdown, by End User

10.2.1.7 Spain: Western Europe Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)

10.2.1.7.1 Spain: Western Europe Cancer Chemotherapy Market Breakdown, by Therapy Type
10.2.1.7.2 Spain: Western Europe Cancer Chemotherapy Market Breakdown, by Indication
10.2.1.7.3 Spain: Western Europe Cancer Chemotherapy Market Breakdown, by End User

10.2.1.8 Switzerland: Western Europe Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)

10.2.1.8.1 Switzerland: Western Europe Cancer Chemotherapy Market Breakdown, by Therapy Type
10.2.1.8.2 Switzerland: Western Europe Cancer Chemotherapy Market Breakdown, by Indication
10.2.1.8.3 Switzerland: Western Europe Cancer Chemotherapy Market Breakdown, by End User

10.2.1.9 Sweden: Western Europe Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)

10.2.1.9.1 Sweden: Western Europe Cancer Chemotherapy Market Breakdown, by Therapy Type
10.2.1.9.2 Sweden: Western Europe Cancer Chemotherapy Market Breakdown, by Indication
10.2.1.9.3 Sweden: Western Europe Cancer Chemotherapy Market Breakdown, by End User

10.2.1.10 Austria: Western Europe Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)

10.2.1.10.1 Austria: Western Europe Cancer Chemotherapy Market Breakdown, by Therapy Type
10.2.1.10.2 Austria: Western Europe Cancer Chemotherapy Market Breakdown, by Indication
10.2.1.10.3 Austria: Western Europe Cancer Chemotherapy Market Breakdown, by End User

10.2.1.11 the United Kingdom: Western Europe Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)

10.2.1.11.1 the United Kingdom: Western Europe Cancer Chemotherapy Market Breakdown, by Therapy Type
10.2.1.11.2 the United Kingdom: Western Europe Cancer Chemotherapy Market Breakdown, by Indication
10.2.1.11.3 the United Kingdom: Western Europe Cancer Chemotherapy Market Breakdown, by End User

10.2.1.12 Denmark: Western Europe Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)

10.2.1.12.1 Denmark: Western Europe Cancer Chemotherapy Market Breakdown, by Therapy Type
10.2.1.12.2 Denmark: Western Europe Cancer Chemotherapy Market Breakdown, by Indication
10.2.1.12.3 Denmark: Western Europe Cancer Chemotherapy Market Breakdown, by End User

10.2.1.13 Portugal: Western Europe Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)

10.2.1.13.1 Portugal: Western Europe Cancer Chemotherapy Market Breakdown, by Therapy Type
10.2.1.13.2 Portugal: Western Europe Cancer Chemotherapy Market Breakdown, by Indication
10.2.1.13.3 Portugal: Western Europe Cancer Chemotherapy Market Breakdown, by End User

10.2.1.14 Norway: Western Europe Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)

10.2.1.14.1 Norway: Western Europe Cancer Chemotherapy Market Breakdown, by Therapy Type
10.2.1.14.2 Norway: Western Europe Cancer Chemotherapy Market Breakdown, by Indication
10.2.1.14.3 Norway: Western Europe Cancer Chemotherapy Market Breakdown, by End User

10.2.1.15 and Finland: Western Europe Cancer Chemotherapy Market – Revenue and Forecast to 2031 (US$ Million)

10.2.1.15.1 and Finland: Western Europe Cancer Chemotherapy Market Breakdown, by Therapy Type
10.2.1.15.2 and Finland: Western Europe Cancer Chemotherapy Market Breakdown, by Indication
10.2.1.15.3 and Finland: Western Europe Cancer Chemotherapy Market Breakdown, by End User

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Industry Landscape

12.1 Overview

12.2 Market Initiative

12.3 Partnerships and Collaborations

12.4 Other Developments

13. Company Profiles

13.1 Astellas Pharma Inc

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Eli Lilly and Co

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Novartis AG

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Merck KGaA

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Johnson & Johnson

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 AstraZeneca

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Pfizer Inc

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Bristol Myers Squibb

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 F. Hoffmann-La Roche Ltd

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 AbbVie

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

14.2 List of Abbreviations

Western Europe Cancer Chemotherapy Market Outlook (2021–2031)